Showing results (501-510 of 538) with videos related to
Sort By:
Pageof 54
Nature|November 28, 2014
An impenetrable barrier to ultrarelativistic electrons in the Van Allen radiation beltsD N Baker, A N Jaynes, V C Hoxie, et al.Viruses|December 23, 2022
In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-ProteinBruna Andersen Pereira de Jesus, Anderson Albino Gomes, Alex E Clark, et al.Breast Cancer Research and Treatment|July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancerHope S Rugo, Olivier Trédan, Jungsil Ro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneLinda T Vahdat, Brian Pruitt, Carol J Fabian, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialJ K Litton, S A Hurvitz, L A Mina, et al.JNCI Cancer Spectrum|April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care ChemotherapyHope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.Clinical Breast Cancer|February 14, 2008
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriersTara M Friebel, Susan M Domchek, Susan L Neuhausen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudyStephen E Jones, James Cantrell, Svetislava Vukelja, et al.Breast Cancer Research and Treatment|January 25, 2014
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriersJoanne Kotsopoulos, Jan Lubinski, Pal Moller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Stephen Jones, Frankie Ann Holmes, Joyce O'Shaughnessy, et al.Pageof 54